Because TGF-β and AURKA signaling pathways provide attractive druggable targets to halt tumor progression, we developed tumor xenografts to define in vivo the efficacy of dual TGF-β/AURKA targeted therapy in combination with DTX. The gene discussed is AURKA; the disease is neoplasm.